Luteal phase support for assisted reproduction cycles

Linden, M. van der; Buckingham, Karen; Farquhar, Cindy; Kremer, J.A.M.; Metwally, Mostafa

doi:10.1002/14651858.cd009154

Cited by 151 publications

(197 citation statements)

References 17 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…Certainly, the effect of progesterone supplementation during luteal phase in IVF cycles has been addressed in several studies, and there is more consensus with regard to its beneficial role on reproductive outcomes [8]. However, this effect seems less consistent in IUI cycles.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis

Miralpeix

González-Comadran

Solà

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To evaluate the efficacy of luteal phase support with vaginal progesterone in women undergoing intrauterine insemination (IUI). Methods Systematic review and meta-analysis. Randomized controlled trials (RCT) comparing supplementation of luteal phase with vaginal progesterone among women undergoing IUI versus a control group were included. The main outcome assessed was live birth rate. Results Five RCT met the inclusion criteria. In all 1,271 patients were included (951 IUI cycles in the progesterone group, 935 in the control group). Women treated with vaginal progesterone achieved significantly higher live birth rate (risk ratio [RR] 1.94, 95 % confidence interval [CI] 1.36 to 2.77,), and clinical pregnancy rate (RR 1.41, 95 % CI 1.14 to 1.76) as compared with controls. In the subgroup analysis per stimulation protocol, this beneficial effect of receiving progesterone was only observed in the group stimulated with gonadotropins (RR 2.28, 95 % CI 1.49 to 3.51), compared to the group stimulated with clomiphene citrate (CC) (RR 1.30, 95 % CI 0.68 to 2.50). No differences were observed in the miscarriage and multiple pregnancy rates. Conclusions The supplementation of luteal phase with vaginal progesterone significantly increases live birth among women undergoing IUI when receiving gonadotropins for ovulation induction. Women receiving CC to induce ovulation do not seem to benefit from this treatment.Capsule Luteal phase support with vaginal progesterone in women undergoing intrauterine insemination significantly improves live birth rate. E. Miralpeix : M. González-Comadran : R. Carreras :

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis

Miralpeix

González-Comadran

Solà

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…After IUI, luteal phase support using 400 mg cyclogest was provided to all patients. It has been suggested progesterone seems to be the best option for luteal phase support, with better pregnancy results when synthetic progesterone is used [36]. In one RCT comparing low-dose hMG (75 iu) versus CC in subfertile couples treated with intrauterine insemination, IUI was performed 1 day (27-30 h) after hCG [27] giving better pregnancy rates in the hMG group.…”

Section: Discussionmentioning

confidence: 99%

Factors Leading to Pregnancies in Stimulated Intrauterine Insemination Cycles and the Use of Consecutive Ejaculations Within a Small Clinic Environment

Bahadur

Almossawi

IIlahibuccus

et al. 2016

J Obstet Gynecol India

View full text Add to dashboard Cite

Introduction Understanding and improving IUI pregnancy rates has enormous global appeal and application. This pilot study goes one step further by utilising consecutive ejaculates from men with oligozoospermia and comparing with normozoospermic male group. Materials and Methods A retrospective analysis was performed on 117 IUI-stimulated treatment cycles in a small fertility clinic in North Middlesex University Hospitals Trust, UK, within a NHS setting. Risks of OHSS and multiple births are carefully controlled. Results In our cohort, several factors are associated with positive IUI pregnancies and these were: age of the woman, inseminating with C5 total progressive motile sperm; having C50 % Grade A sperm progression and having C1 Dr. Gulam Bahadur is a past member of the HFEA. His main involvement is in andrology with special emphasis on diagnostic analyses, male cancer patients, counselling, sperm donor recruitment and sperm freezing, and recovery rates following cryopreservation. Important ways to optimise pregnancy rates in simple first-line treatment intrauterine insemination are being researched and applied within a number of UK NHS Trust Hospitals. Dr Bahadur has made significant contributions to the understanding of semen qualities in subfertile males, cancer patients, adolescent cancer patients and produced one of the first reports on ovarian tissue freezing for cancer patients.The Journal of Obstetrics and Gynecology of India (September-October 2016) 66(S1):S513-S520 DOI 10.1007/s13224-016-0876-0 123follicle achieved with a realistic hMG dosage, hCG trigger and IUI of 29.7 h (2.5-38.4 h), with an endometrial thickness of 10.7 mm (6.6-13.4 mm). Bifollicular presence in at least half the cases along with hMG protocols added usefully to the pregnancy outcomes. Conclusions The pregnancy rates per cycle were 19 and 23 % in the consecutive ejaculates and non-consecutive ejaculate groups, respectively, P = 0.59. For the whole cohort, the pregnancy rate was 20.51 % per cycle and 33.8 % per women. This approach if validated with large RCT will have universally beneficial effects.

show abstract

“…Fresh single-embryo transfers performed on day 3 to all women [14]. Luteal support was given by vaginal progesterone (Crinone 8 % gel, Serono, Istanbul), and supplementation was started on hCG administration day [15]. Pregnancy was determined by βhCG levels in blood tests performed 14 days after embryo transfer, and clinical pregnancy was defined as the presence of a gestational sac with accompanying fetal heartbeat.…”

Section: In Vitro Fertilization Stimulationmentioning

confidence: 99%

The effect of serum and follicular fluid amyloid-associated protein levels on in vitro fertilization outcome in patients with polycystic ovary syndrome

Tımur

Yimaz

Kahyaoğlu

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose In this study, we aimed to investigate serum and follicular fluid amyloid A protein levels in non-obese nonhyperandrogenic patients with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF) and IVF outcome. Methods A total of 81 patients undergoing IVF treatment, 41 patients diagnosed as PCOS according to the Rotterdam criteria (group I) and 40 patients with the etiology of male factor infertility (group II), were included in the study. On the day of oocyte pickup, serum and follicular fluid samples were collected from all patients. Results Serum E2 level on the day of hCG (2849.93±541.54 vs. 2494.28±712.98) and total number of retrieved oocytes (13.73±3.57 vs. 10.53±4.07) were significantly higher in group I when compared to group II (p<0.05). However, number of mature oocytes, fertilization rate, and clinical pregnancy rate did not differ (p>0.05). No significant difference was found between two groups regarding the serum and follicular fluid amyloid A protein levels on the day of oocyte retrieval (p>0.05).

show abstract

Luteal phase support for assisted reproduction cycles

Cited by 151 publications

References 17 publications

Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis

Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: a systematic review and meta-analysis

Factors Leading to Pregnancies in Stimulated Intrauterine Insemination Cycles and the Use of Consecutive Ejaculations Within a Small Clinic Environment

The effect of serum and follicular fluid amyloid-associated protein levels on in vitro fertilization outcome in patients with polycystic ovary syndrome

Contact Info

Product

Resources

About